**Question:** Glycogen storage diseases include all the following except

A. Pompe disease
B. McArdle disease
C. Tay-Sachs disease
D. Tay-Sachs disease

**Correct Answer:** C. Tay-Sachs disease

**Core Concept:** Glycogen storage diseases (GSDs) are a group of rare, inherited disorders characterized by the accumulation of glycogen in various tissues and organs due to deficiency or dysfunction of specific enzymes involved in glycogen synthesis, degradation, or remodeling. These diseases primarily affect the liver, muscles, and/or the nervous system.

**Why the Correct Answer is Right:** Tay-Sachs disease (HSAN type I) is not a glycogen storage disease but rather a lysosomal storage disorder. Albeit related, the correct classification for Tay-Sachs disease is as a fatty acid storage disease due to deficiency of hexosaminidase A and B enzymes, responsible for breaking down sphingolipids, rather than glycogen.

**Why Each Wrong Option is Incorrect:**

A. Pompe disease (acid maltase deficiency) is a glycogen storage disease affecting the muscles and heart, caused by deficiency of acid maltase enzyme involved in glycogen breakdown.
B. McArdle disease (myophosphorylase deficiency) is another glycogen storage disease affecting muscles, caused by deficiency of phosphofructokinase enzyme involved in glycogen breakdown.
D. Tay-Sachs disease (HSAN type I) is a lysosomal storage disorder due to hexosaminidase A and B deficiency, not a glycogen storage disease.

**Why Correct Answer is Right:** Tay-Sachs disease (HSAN type I) is a lysosomal storage disorder due to hexosaminidase A and B deficiency, not a glycogen storage disease. In glycogen storage diseases, the primary issue involves glycogen synthesis, degradation, or remodeling enzymes, resulting in abnormal glycogen accumulation. In contrast, Tay-Sachs disease is characterized by the accumulation of gangliosides, particularly GM2 gangliosides, due to hexosaminidase deficiency, primarily affecting the nervous system.

**Clinical Pearls:**

Tay-Sachs disease is a rare autosomal recessive disorder that typically presents in infancy or early childhood with progressive neurological deterioration, muscle weakness, and vision loss. In contrast, glycogen storage diseases usually involve systemic symptoms, such as hepatomegaly, cardiomyopathy, and skeletal muscle involvement. Accurate identification of the type of storage disorder is crucial for appropriate management and prognosis. While both lysosomal storage disorders and glycogen storage diseases share some overlapping features, they differ in the primary defect and affected tissues, making the correct classification essential for appropriate diagnosis and treatment.